MXPA05009303A - Dosage forms comprising ag013736. - Google Patents

Dosage forms comprising ag013736.

Info

Publication number
MXPA05009303A
MXPA05009303A MXPA05009303A MXPA05009303A MXPA05009303A MX PA05009303 A MXPA05009303 A MX PA05009303A MX PA05009303 A MXPA05009303 A MX PA05009303A MX PA05009303 A MXPA05009303 A MX PA05009303A MX PA05009303 A MXPA05009303 A MX PA05009303A
Authority
MX
Mexico
Prior art keywords
dosage forms
admnistering
prodrugs
solvates
cancers
Prior art date
Application number
MXPA05009303A
Other languages
Spanish (es)
Inventor
Marie Steinfeldt Heidi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA05009303A publication Critical patent/MXPA05009303A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides dosage forms of a compound of formula (1) or pharmaceutically acceptable salts, solvates or prodrugs thereof. The invention further provides methods of treating abnormal cell growth, such as cancers, by admnistering the dosage forms to a mammal.
MXPA05009303A 2003-04-03 2004-03-17 Dosage forms comprising ag013736. MXPA05009303A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31
PCT/IB2004/000867 WO2004087152A1 (en) 2003-04-03 2004-03-17 Dosage forms comprising ag013736

Publications (1)

Publication Number Publication Date
MXPA05009303A true MXPA05009303A (en) 2005-10-05

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009303A MXPA05009303A (en) 2003-04-03 2004-03-17 Dosage forms comprising ag013736.

Country Status (16)

Country Link
US (1) US20040224988A1 (en)
EP (1) EP1613320A1 (en)
JP (1) JP2006522087A (en)
KR (1) KR20050119671A (en)
AR (1) AR043822A1 (en)
AU (1) AU2004226586B2 (en)
BR (1) BRPI0409230A (en)
CA (1) CA2520932A1 (en)
MX (1) MXPA05009303A (en)
NL (1) NL1025873C2 (en)
NO (1) NO20055143L (en)
PA (1) PA8599701A1 (en)
RU (2) RU2341263C2 (en)
TW (1) TW200423933A (en)
UY (1) UY28255A1 (en)
WO (1) WO2004087152A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509580A (en) * 2004-03-30 2007-11-27 Pfizer Prod Inc signal transduction inhibitor combinations
KR20070058690A (en) * 2004-11-02 2007-06-08 화이자 인코포레이티드 Methods of preparing indazole compounds
CN101052633A (en) * 2004-11-02 2007-10-10 辉瑞大药厂 Methods of preparing indazole compounds
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
NZ580126A (en) 2007-04-05 2012-03-30 Pfizer Prod Inc Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
ES2591281T3 (en) * 2007-07-12 2016-11-25 Gitr, Inc. Combination therapies that employ GITR binding molecules
CA2729303A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
MX2014003886A (en) 2011-09-30 2014-05-13 Pfizer Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl- vinyl)-1h-indazol-6-ylsulfanyl]-benzamide.
CA2855211A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
ES2899457T3 (en) 2014-02-04 2022-03-11 Pfizer Combination of a PD-1 antagonist and a VEGFR inhibitor to treat cancer
JP6414727B2 (en) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 Treatment / preventive agent for joint diseases
CN104013589A (en) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 Axitinib orally disintegrating tablet and preparation method thereof
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US10800846B2 (en) 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
WO2016205277A1 (en) 2015-06-16 2016-12-22 Merck Patent Gmbh Pd-l1 antagonist combination treatments
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
IL265762B2 (en) 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2023166418A2 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69333807T2 (en) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en) * 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (en) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 Optical power measurement system and terminal station and repeater therefor
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
AR043822A1 (en) 2005-08-17
PA8599701A1 (en) 2004-11-26
US20040224988A1 (en) 2004-11-11
BRPI0409230A (en) 2006-03-28
NL1025873C2 (en) 2006-02-14
RU2005128791A (en) 2006-05-10
CA2520932A1 (en) 2004-10-14
NO20055143D0 (en) 2005-11-02
UY28255A1 (en) 2004-11-30
EP1613320A1 (en) 2006-01-11
AU2004226586B2 (en) 2008-12-11
JP2006522087A (en) 2006-09-28
RU2341263C2 (en) 2008-12-20
RU2008122358A (en) 2009-12-10
AU2004226586A1 (en) 2004-10-14
WO2004087152A1 (en) 2004-10-14
NL1025873A1 (en) 2004-10-05
KR20050119671A (en) 2005-12-21
TW200423933A (en) 2004-11-16
NO20055143L (en) 2006-01-03

Similar Documents

Publication Publication Date Title
MXPA05009303A (en) Dosage forms comprising ag013736.
DE60329001D1 (en) 8-hydroxychinolinderivate
MXPA05006420A (en) Pyrimidine derivates for the treatment of abnormal cell growth.
RS20050180A (en) Novel benzoimidazole derivatives useful as antiproliferative agensts
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MX2009004096A (en) Talarazole metabolites.
EA200870117A1 (en) AZAINDOL INHIBITORS AURORA-KINAZ
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
YU95102A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MX2007013624A (en) Protein kinase inhibitors.
MXPA02003977A (en) INHIBITORS OF agr;L.
TW200637539A (en) CTGF inhibitors
MXPA05013151A (en) 3-fluoro-piperidines as nmda/nr2b antagonists.
MY138826A (en) 2,7-substituted indoles
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
PL1845780T3 (en) Uses of methylphenidate derivatives
HK1057886A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
DE602006013828D1 (en) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
MXPA03005374A (en) Antitumoral carbazoles.